Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016

Joseph S. Ross, Stefanie Rohde, Lindsey Sangaralingham, Juan Brito Campana, Lauren Choi, Sarah K. Dutcher, David J. Graham, Marjorie R. Jenkins, Kasia J. Lipska, Martin Mendoza, Yandong Qiang, Zhong Wang, Yute Wu, Xiaoxi Yao, Nilay D Shah

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

CONTEXT: Generic drugs account for 9 out of 10 prescriptions dispensed in the United States but for a lower proportion of commonly prescribed thyroid hormone replacement therapies. OBJECTIVE: Characterize temporal patterns of generic and brand-name thyroid hormone drug use, including patient and prescriber characteristics associated with brand-name use. DESIGN AND SETTING: Cross-sectional longitudinal analysis of national data from a large administrative claims database from January 2007 through December 2016. PATIENTS: Adults with insurance coverage through commercial, Medicare Advantage, and Medicare Part D health plans. MAIN OUTCOME MEASURES: Generic and brand-name thyroid hormone drug use. RESULTS: From 2007 to 2016, the annual number of thyroid hormone treatment pharmacy fills increased from 8,905,836 in 2007 to 11,613,923 in 2016, 73.6% of which were for generic levothyroxine, 23.4% for brand-name levothyroxine, and the remaining for other formulations. Dispensing of generic thyroid hormone drugs increased from 59.8% in 2007 to 84.9% in 2016 and was consistently higher among Medicare Advantage and Medicare Part D when compared with the commercial beneficiary population. For all three beneficiary populations, use of brand-name products was less common among older adults and more common among women and those receiving prescriptions from endocrinologists and was more common among those of white race and with greater household income for the Medicare Advantage and commercial beneficiary populations (P < 0.001). CONCLUSIONS: Brand-name thyroid hormone product use declined from 2007 to 2016 among three large, national insurer beneficiary populations. Although certain patient characteristics were associated with brand-name use, prescriber specialty was the strongest predictor.

Original languageEnglish (US)
Pages (from-to)2305-2314
Number of pages10
JournalThe Journal of clinical endocrinology and metabolism
Volume104
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Medicare
Thyroid Hormones
Names
Medicare Part C
Pharmaceutical Preparations
Medicare Part D
Thyroxine
Population
Prescriptions
Generic Drugs
Insurance
Insurance Carriers
Insurance Coverage
Hormone Replacement Therapy
Health
Cross-Sectional Studies
Databases

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. / Ross, Joseph S.; Rohde, Stefanie; Sangaralingham, Lindsey; Brito Campana, Juan; Choi, Lauren; Dutcher, Sarah K.; Graham, David J.; Jenkins, Marjorie R.; Lipska, Kasia J.; Mendoza, Martin; Qiang, Yandong; Wang, Zhong; Wu, Yute; Yao, Xiaoxi; Shah, Nilay D.

In: The Journal of clinical endocrinology and metabolism, Vol. 104, No. 6, 01.06.2019, p. 2305-2314.

Research output: Contribution to journalArticle

Ross, JS, Rohde, S, Sangaralingham, L, Brito Campana, J, Choi, L, Dutcher, SK, Graham, DJ, Jenkins, MR, Lipska, KJ, Mendoza, M, Qiang, Y, Wang, Z, Wu, Y, Yao, X & Shah, ND 2019, 'Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016', The Journal of clinical endocrinology and metabolism, vol. 104, no. 6, pp. 2305-2314. https://doi.org/10.1210/jc.2018-02197
Ross, Joseph S. ; Rohde, Stefanie ; Sangaralingham, Lindsey ; Brito Campana, Juan ; Choi, Lauren ; Dutcher, Sarah K. ; Graham, David J. ; Jenkins, Marjorie R. ; Lipska, Kasia J. ; Mendoza, Martin ; Qiang, Yandong ; Wang, Zhong ; Wu, Yute ; Yao, Xiaoxi ; Shah, Nilay D. / Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. In: The Journal of clinical endocrinology and metabolism. 2019 ; Vol. 104, No. 6. pp. 2305-2314.
@article{16b5e552a43d4c29ab02e75bf201698f,
title = "Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016",
abstract = "CONTEXT: Generic drugs account for 9 out of 10 prescriptions dispensed in the United States but for a lower proportion of commonly prescribed thyroid hormone replacement therapies. OBJECTIVE: Characterize temporal patterns of generic and brand-name thyroid hormone drug use, including patient and prescriber characteristics associated with brand-name use. DESIGN AND SETTING: Cross-sectional longitudinal analysis of national data from a large administrative claims database from January 2007 through December 2016. PATIENTS: Adults with insurance coverage through commercial, Medicare Advantage, and Medicare Part D health plans. MAIN OUTCOME MEASURES: Generic and brand-name thyroid hormone drug use. RESULTS: From 2007 to 2016, the annual number of thyroid hormone treatment pharmacy fills increased from 8,905,836 in 2007 to 11,613,923 in 2016, 73.6{\%} of which were for generic levothyroxine, 23.4{\%} for brand-name levothyroxine, and the remaining for other formulations. Dispensing of generic thyroid hormone drugs increased from 59.8{\%} in 2007 to 84.9{\%} in 2016 and was consistently higher among Medicare Advantage and Medicare Part D when compared with the commercial beneficiary population. For all three beneficiary populations, use of brand-name products was less common among older adults and more common among women and those receiving prescriptions from endocrinologists and was more common among those of white race and with greater household income for the Medicare Advantage and commercial beneficiary populations (P < 0.001). CONCLUSIONS: Brand-name thyroid hormone product use declined from 2007 to 2016 among three large, national insurer beneficiary populations. Although certain patient characteristics were associated with brand-name use, prescriber specialty was the strongest predictor.",
author = "Ross, {Joseph S.} and Stefanie Rohde and Lindsey Sangaralingham and {Brito Campana}, Juan and Lauren Choi and Dutcher, {Sarah K.} and Graham, {David J.} and Jenkins, {Marjorie R.} and Lipska, {Kasia J.} and Martin Mendoza and Yandong Qiang and Zhong Wang and Yute Wu and Xiaoxi Yao and Shah, {Nilay D}",
year = "2019",
month = "6",
day = "1",
doi = "10.1210/jc.2018-02197",
language = "English (US)",
volume = "104",
pages = "2305--2314",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016

AU - Ross, Joseph S.

AU - Rohde, Stefanie

AU - Sangaralingham, Lindsey

AU - Brito Campana, Juan

AU - Choi, Lauren

AU - Dutcher, Sarah K.

AU - Graham, David J.

AU - Jenkins, Marjorie R.

AU - Lipska, Kasia J.

AU - Mendoza, Martin

AU - Qiang, Yandong

AU - Wang, Zhong

AU - Wu, Yute

AU - Yao, Xiaoxi

AU - Shah, Nilay D

PY - 2019/6/1

Y1 - 2019/6/1

N2 - CONTEXT: Generic drugs account for 9 out of 10 prescriptions dispensed in the United States but for a lower proportion of commonly prescribed thyroid hormone replacement therapies. OBJECTIVE: Characterize temporal patterns of generic and brand-name thyroid hormone drug use, including patient and prescriber characteristics associated with brand-name use. DESIGN AND SETTING: Cross-sectional longitudinal analysis of national data from a large administrative claims database from January 2007 through December 2016. PATIENTS: Adults with insurance coverage through commercial, Medicare Advantage, and Medicare Part D health plans. MAIN OUTCOME MEASURES: Generic and brand-name thyroid hormone drug use. RESULTS: From 2007 to 2016, the annual number of thyroid hormone treatment pharmacy fills increased from 8,905,836 in 2007 to 11,613,923 in 2016, 73.6% of which were for generic levothyroxine, 23.4% for brand-name levothyroxine, and the remaining for other formulations. Dispensing of generic thyroid hormone drugs increased from 59.8% in 2007 to 84.9% in 2016 and was consistently higher among Medicare Advantage and Medicare Part D when compared with the commercial beneficiary population. For all three beneficiary populations, use of brand-name products was less common among older adults and more common among women and those receiving prescriptions from endocrinologists and was more common among those of white race and with greater household income for the Medicare Advantage and commercial beneficiary populations (P < 0.001). CONCLUSIONS: Brand-name thyroid hormone product use declined from 2007 to 2016 among three large, national insurer beneficiary populations. Although certain patient characteristics were associated with brand-name use, prescriber specialty was the strongest predictor.

AB - CONTEXT: Generic drugs account for 9 out of 10 prescriptions dispensed in the United States but for a lower proportion of commonly prescribed thyroid hormone replacement therapies. OBJECTIVE: Characterize temporal patterns of generic and brand-name thyroid hormone drug use, including patient and prescriber characteristics associated with brand-name use. DESIGN AND SETTING: Cross-sectional longitudinal analysis of national data from a large administrative claims database from January 2007 through December 2016. PATIENTS: Adults with insurance coverage through commercial, Medicare Advantage, and Medicare Part D health plans. MAIN OUTCOME MEASURES: Generic and brand-name thyroid hormone drug use. RESULTS: From 2007 to 2016, the annual number of thyroid hormone treatment pharmacy fills increased from 8,905,836 in 2007 to 11,613,923 in 2016, 73.6% of which were for generic levothyroxine, 23.4% for brand-name levothyroxine, and the remaining for other formulations. Dispensing of generic thyroid hormone drugs increased from 59.8% in 2007 to 84.9% in 2016 and was consistently higher among Medicare Advantage and Medicare Part D when compared with the commercial beneficiary population. For all three beneficiary populations, use of brand-name products was less common among older adults and more common among women and those receiving prescriptions from endocrinologists and was more common among those of white race and with greater household income for the Medicare Advantage and commercial beneficiary populations (P < 0.001). CONCLUSIONS: Brand-name thyroid hormone product use declined from 2007 to 2016 among three large, national insurer beneficiary populations. Although certain patient characteristics were associated with brand-name use, prescriber specialty was the strongest predictor.

UR - http://www.scopus.com/inward/record.url?scp=85065556950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065556950&partnerID=8YFLogxK

U2 - 10.1210/jc.2018-02197

DO - 10.1210/jc.2018-02197

M3 - Article

C2 - 30690529

AN - SCOPUS:85065556950

VL - 104

SP - 2305

EP - 2314

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -